Nous Biosciences Inc
Publicly observedDoylestown, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Doylestown | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Nous Biosciences Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | WS4XBLGG9X65 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant3 Sept 2025Publicly observed
NIH SBIR/STTR award: Combination of formulated dolcanatide, a guanylate cyclase-C agonist, with formulated atiprimod, a JAK-STAT inhibitor, for treatment of murine colitis.
USD 358,039.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2024Publicly observed
NIH SBIR/STTR award: Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis
USD 90,723.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.